Success Metrics

Clinical Success Rate

57.1%

Based on 4 completed trials

Completion Rate

57%(4/7)

Active Trials

0(0%)

Results Posted

75%(3 trials)

Terminated

3(43%)

Phase Distribution

Ph phase_1

86%

Ph early_phase_1

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 1Safety & dosage

6(85.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(3)

Detailed Status

Completed4

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

57.1%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 11 (14.3%)

Phase 16 (85.7%)

Trials by Status

terminated343%

completed457%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_1

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

NCT04364230

completedphase_1

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

NCT03617328

terminatedearly_phase_1

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

NCT02382549

terminatedphase_1

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

NCT02425306

completedphase_1

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

NCT02515227

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT04364230Phase 1

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed

NCT03617328Phase 1

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed

NCT02382549Early Phase 1

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

Terminated

NCT02425306Phase 1

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Terminated

NCT02515227Phase 1

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

Completed

NCT02385669Phase 1

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

Terminated

NCT00089219Phase 1

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7